Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 11/20 | 0.47 |
| ▸ | DRD2 | P14416 | 6/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735433 | 0.93 | DRD3 (0.46) | DRD3DRD2DRD4HTR1AFYN | |
| SCHEMBL736798 | 0.91 | DRD3 (0.44) | DRD3DRD2DRD4HTR1AFYN | |
| SCHEMBL736001 | 0.89 | ADH1A (0.46) | DRD3DRD2DRD4HTR1AFYN | |
| SCHEMBL3376550 | 0.87 | DRD3 (0.50) | DRD3DRD2DRD4HTR1AFYN | |
| SCHEMBL736052 | 0.86 | DRD3 (0.44) | DRD3DRD2DRD4HTR1AFYN | |
| SCHEMBL6967318 | 0.86 | ADH1C (0.37) | DRD3DRD2DRD4HTR1A | |
| SCHEMBL736373 | 0.83 | — | — | |
| SCHEMBL737468 | 0.83 | — | — | |
| SCHEMBL2099636 | 0.80 | DRD3 (0.43) | DRD3DRD2DRD4HTR1AFYN | |
| SCHEMBL15865807 | 0.79 | DRD3 (0.48) | DRD3DRD2DRD4HTR1AFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158397-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2024-05-16 | — | — | US | claimed |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2023-03-21 | — | — | US | claimed |
| US-20230060990-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN KETTERING INST CANCER RES (US) | 2023-03-02 | — | — | US | claimed |
| US-20210138091-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2021-05-13 | — | — | US | claimed |
| EP-3709022-A1 | USES OF LABELED HSP90 INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2020-09-16 | — | — | EP | claimed |
| EP-3208615-B1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2019-10-09 | — | — | EP | claimed |
| US-10336757-B2 | Treatment of neurodegenerative diseases through inhibition of HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-07-02 | — | — | US | claimed |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-02-12 | — | — | US | claimed |
| US-20140378452-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-12-25 | — | — | US | claimed |
| US-20090298857-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-12-03 | — | — | US | claimed |
| US-20240158397-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2024-02-22 | — | — | US | disclosed |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2023-03-21 | — | — | US | disclosed |
| US-20230060990-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN KETTERING INST CANCER RES (US) | 2023-03-02 | — | — | US | disclosed |
| CN-109374889-B | Use of labeled HSP90 inhibitors | 索隆-基特林癌症研究协会 | 2022-04-19 | — | — | CN | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-0870765-B1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARM CO LTD (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-5981557-A | HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0870765-A1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336757-B2 | Treatment of neurodegenerative diseases through inhibition of HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | DRD3 2978/4885DRD2 2965/4885DRD4 3698/4885 |
| US-20140378452-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | DRD3 2978/4885DRD2 2965/4885DRD4 3698/4885 |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | DRD3 4759/4885DRD2 4811/4885DRD4 4828/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | DRD3 531/4885DRD2 365/4885DRD4 607/4885 |
| US-20090298857-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | DRD3 2978/4885DRD2 2965/4885DRD4 3698/4885 |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | HSP90AB1, HSP90AA1, HSP90B1 | DRD3 4441/4885DRD2 4720/4885DRD4 4797/4885 |
| US-20240158397-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | HSP90B1, HSP90AB1, HSP90AB2P | DRD3 3241/4885DRD2 3089/4885DRD4 3562/4885 |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AA1 | DRD3 4759/4885DRD2 4811/4885DRD4 4828/4885 |
| US-20230060990-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | HSP90B1, HSP90AB1, HSP90AB2P | DRD3 3241/4885DRD2 3089/4885DRD4 3562/4885 |
| US-20210138091-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | DRD3 4759/4885DRD2 4811/4885DRD4 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.